• Topics

  • Formats

Dr. Paul Burton, Chief Medical Officer at Amgen, discusses why direct-to-patient models are becoming a bigger part of the future of pharma access.

The conversation explores how patient education, real-world insight and advances in AI could reshape everything from prescription adherence to drug discovery.

Reading this content is completely free

Enjoy Unlimited Access and Unlock
Additional Features with a Free Account

Join Now

You are attempting to log out of MyMA

Do you really want to log out?